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ABSTRACT
Humans are super organisms as they host microorganisms to comprise 90% of cells in body and trillion foreign genes in contrast to <30 thousand of 
their own. That speaks of intricate role of microbes in human health, disease, and even evolution. Medical wisdom on these aspects needs to evolve 
fast as modern society increasingly suffers diseases with epigenetic determinants responsible to a great extent. Appropriate address to microbiome 
is mandated to prevent and manage diseases due to environmental, dietary, lifestyle, and medication effects. Diverse biomedical perspectives of 
microbiome are briefly discussed here.
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MICROBIOME, THE SUPERORGANISM
Over 90% cells in human body are microbial (not human) and about 
a million microbial genes express within us compared to about 20500 
human genes. Body of individuals is indeed an ecosystem inhabited 
by microbes in skin, oral cavity, intestine, and score of other tissue 
including uterine cavity and lungs. Monocytes and macrophages move 
through body carrying microbes and their metabolites. A huge load 
of metabolites - the small molecules generated from the enzymatic 
protein products of over million microbial genes interact with the 
limited number of protein products of our genes. Nuclear receptors are 
natural to have evolved liganding products from microbes associating 
for generations, and impacting undiscovered facets of human biology, 
health, and disease [1-3].
Nobel laureate Joshua Lederberg proposed the term MICROBIOME, 
referring the totality of microbes (commensals and pathogenic), their 
genomes (METAGENOME), and environmental interactions, in a defined 
biological community or niche. Human metagenome is a composite of 
Homo Sapiens genes and genes present in the genomes of the trillions 
of microbes that colonize over adult bodies or the microbiome.
It is obvious that unless the collective human-microbiome 
“SUPERORGANISM” is adequately understood, full understanding of 
health, and disease may not be possible. There is growing appreciation 
that the microbiome plays a key role and active role in the development 
and function of basic physiological processes, including digestion, 
growth, immune defense, and even brain development. Microbiome 
is a dynamic entity, evolving over host’s lifetime, particularly in first 
3 years, wherein stable microbiome is established. Changes in diet, 
stress, infections, drugs, etc., inflict changes in microbiome. Such 
environmental influences meet with lost genetic mechanisms in 
determining the adult core microbiome [4,5].
MICROBIOME IN HUMAN HEALTH AND DISEASE
Microbiome is found important in neurodevelopmental disorders such 
as autism and stress-related disorders in which environmental events 
in early postnatal life become crucial steering developmental process 
on pathological course. The critical period of vulnerability needs sound 
definition in the context [6].
The evidence that composition of gut microbiota can be different 
between healthy and obese or with Type 2 diabetic patients suggests 
the link between gut microbiota and pathophysiology of metabolic 
disease [7]. Several mechanisms appear to link the events in colon to 
regulation of energy metabolism, i.e., the energy harvest from diet, the 
synthesis of gut peptides involved in energy homeostasis (GLP-1, PYY.), 
and the regulation of fat storage. Diet high in usual trans-fatty acids 
and omega-6 acids affects gut microbiota and may propagate metabolic 
endotoxemia leading to typical low-grade chronic inflammation seen 
in diabetes and obesity [8]. Change in gut microbiota, attempted with 
prebiotics (microbes) and probiotics (fiber) is helpful in controlling 
the development of metabolic diseases associated with obesity. Specific 
strategies of modifying gut microbiota to impact on occurrence of 
metabolic diseases would be most worthwhile to evolve [9].
The connections between microbiome and the immune system are 
well established. Gut microbiota regulates Th17 cells and regulatory 
T cell. The development of other specialized T cells is also influenced, 
but specific microbial species are yet unidentified. Earlier, the 
microbes were considered to provoke autoimmunity by mimicry of 
host molecules. The current focus is shifted to microbial metabolites 
and products influencing host immune cell function. Host cell gene 
expression and protein formation are more affected by intracellular 
microbes. The nuclear Vitamin D receptor regulates transcription and 
expression of many immune genes. Many viruses inhibit the expression 
of these Vitamin D receptors and thereby affect immunity. The inherited 
genetic variation involving both common and rare variants probably, 
create a disease-favoring milieu around immune cells. Metabolites from 
gut microbes can influence such milieu. Combined change in milieu 
due to genetic and microbial factors, facilitates epigenetic changes 
through induction or suppression of specific mRNAs or through altered 
expression of chromatin regulators. Such changes, along with specific 
microbial insults, would contribute to induction of autoimmune 
disorders. Recent studies suggest microbiota influence on immune 
system and innate immune susceptibility independently involved 
in the development of inflammatory bowel disease. Replacement of 
commensals flora through fecal transplantation and prebiotics provide 
relief [10,11].
The celiac disease involves altered Th1 and innate response. 
Environmental factors may alter microbiota influencing disease 
development. Gluten-free diet in the patients helps to reverse gut 
flora to normal and renders benefit. Type 1 diabetes is shown to be 
preventable through neonatal exposures to certain microbes and 
their byproducts, in babies with genetic susceptibility the disease. 
Psoriasis involves disruption of cutaneous immune responses, and 
differences are seen in bacteria in psoriatic skin lesions and the 
Review Article
Innovare Journal of Medical Science, Vol 5, Issue 1, 2017, 4-5
 Pandey and Pandey 
5
uninvolved skin. Viral dysbiosis is implicated in multiple sclerosis, 
causing activation of autoreactive T cells in central nervous system 
which recruit autoantibody producing B lymphocytes. Both host 
and environmental factors interplay in etiology of rheumatoid 
arthritis. Immune alteration inflicted by microbes is implicated in 
pathogenesis. In predisposed individuals, local immune response 
appears to promote systemic autoimmunity involving autoreactive 
Th17 cells and B cell activation and autoantibody production. 
Interactions between gut commensals and host gender and genetic 
background influence susceptibility to rheumatoid arthritis. 
Antibiotics display benefit, further supporting role of the microbiome. 
Microbiome researches are progressing in a big way to define the 
roles in autoimmune disease induction, progression, maintenance, 
and therapy [12-14].
CURRENT BIOMEDICAL PERSPECTIVES
Several questions demand answers for biomedical understanding 
of microbiome pertaining to organismal and genetic diversity of 
human gut microbiome. How diverse it is among individuals and 
variation within an individual over time. How are a microbiota and 
microbiome transmitted following birth, what is relative role of early 
environmental exposures (to microbes and diets) versus our human 
genotype in defining postnatal microbial community assembly, and 
the structures of our adult microbiota? Is there a core microbiome 
shared between humans, and should this core be defined in terms 
of organisms, genes or functional characteristics? Finally, are there 
genes and/or metabolic pathways in the human microbiome that 
can be identified as being associated to the disease? The field of 
metagenomics emerged from rapid advances in DNA sequencing 
methods, with a focus on the use of culture-independent methods to 
study the structures, functions, and dynamic operations of microbial 
communities. It extends also to the profiling of gene expression at the 
level of RNA (meta-transcription) and protein (meta-proteonis) as 
well as community metabolism (metabolomics). There is promise of 
advancement in understanding of host-microbe interactions in health 
and disease and the potential for therapeutic manipulation of the 
microbiota.
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